February 2012

Forward-looking Statements

Information contained in this presentation may contain forward-looking statements, including, but not limited to: the expectation that Easy Check and GlucoChip will eliminate the patient’s need to prick his/her finger multiple times per day, the expectation that GlucoChip will have a one-year life span, that the product launch of iglucose is expected by early 2012, and the development timeline provided for iglucose, Easy Check and GlucoChip. These forward-looking statements are not statements of historical fact and represent only PositiveID Corporation's beliefs regarding future performance, which is inherently uncertain. There are a variety of factors, many of which are beyond the control of PositiveID Corporation, which affect operations, performance, business strategy and results and could cause actual results and experience to differ materially from the expectations and objectives expressed in any forward-looking statements. Additional information about these and other factors that could affect PositiveID Corporation's business is set forth in PositiveID Corporation's various filings with the Securities and Exchange Commission, including those set forth in PositiveID Corporation's Form 10-K filed on March 25, 2011, and Forms 10-Q filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption “Risk Factors.” PositiveID Corporation undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

2

Key Facts

Symbol OTCBB: PSID

Corporate Headquarters Delray Beach, FL

Stock Price (2/1/12) || 52-Week Range $0.14 || $0.12-$0.74

Shares Outstanding 80,381,659

Market Cap $7.9M

Volume (Daily 90-Day Average) 271,916

Long-Term Debt (9/30/11) $0.00

Full-Time Employees 18

Fiscal Year December 31

Accounting Firm EisnerAmper LLP

3

PositiveID Summary

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection products.

It’s key products are: iglucose – automatic wireless communication of blood sugar

readings Easy Check – non-invasive breath detection of glucose levels GlucoChip – implantable RFID glucose-sensing microchip M-BAND – sample processing and detection of airborne bio-

threats Dragonfly – disposable cartridge for biological sample

processing and detection (rapid PCR) for biodefense and clinical applications

4

Easy-to-use, patent-pending wireless device that connects and communicates automatically from existing data-capable glucometers FDA clearance received November 2011

Collects, records and transmits a patient’s blood glucose data from a glucometer to the iglucose online database

iglucose correlates data and sends glucose readings via text message, email or fax to family member, caregiver, physician or other designee

Integrated iglucometer with “iglucose inside” prototype complete; combines FDA-cleared glucometer technology with iglucose communication platform

Global market for glucometers and strips is forecast to reach $18B by 2015*

Three-year wireless communication agreement with AT&T Wireless communication agreement with Rogers Wireless and CanCare

to launch in Canada Commitment to purchase a minimum of 28,000 units

TM

5*Source: Global Industry Analysts’ “Blood Glucose Meters and Strips: A Global Strategic Business Report,” October 2010

iglucose Market OpportunityAssumptions

• Total market size equals 25 million diabetics in the U.S.

• End user sale price of $90 device• Monthly subscription of $10 (annualized $120)• Strip sales - $0.05 per strip per reading, @ three

readings/dayAssumptions

Timeline

• 510(k) clearance received Nov. 2011• Commercial launch expected in Q1 2012

Total annual market size for device sales

Total annual market size for monthly subscription

Total annual market size for strip sales

5% 10% 25% 50%Market penetration*

$150 $300

$750

$1,500

5% 10% 25% 50%Market penetration*

5% 10% 25% 50%Market penetration*

$113 $225

$563

$1,125

$68 $137

$342

$684

6

(Device sales and recurring revenue in $ millions on annual basis)

Easy Check™ breath glucose detection device, under development, is a non-invasive glucose detection system that measures acetone levels in a patient’s exhaled breath

The association between acetone levels in the breath and glucose is well documented

A handheld, battery-operated, portable, easy-to-use device that includes:

Advanced laser optical sensor, state-of-the-art microprocessor, patent-pending chemical sensors

The goal: patient exhales into the device to test glucose levels without the sample of blood presently required by existing glucometers

Utilizes single-use capsule containing proprietary sodium nitroprusside-based reagent that triggers a chemical reaction that is be measured and correlated to glucose levels

Preliminary lab tests reveal positive results within industry standards for glucometers as set by the National Committee of Clinical Laboratory Standards (currently Clinical and Laboratory Standards Institute – NCCL) and the International Organization for Standardization (ISO)

Could eliminate a patient’s need to prick his/her finger multiple times a day to get glucose readings

Patent pending

Easy Check Breath Device

7

Easy Check Market Opportunity

Assumptions

• Total market size equals 25 million diabetics in the U.S.

• End user sale price of $100 device• Replaceable single-use cartridge at $1.00 each

• Five readings/day = over 1,800 readings/year(Device sales and recurring revenue in $ millions on annual basis)

Timeline

• Multi-variable/sensitivity testing through 2011

• Clinical studies to commence by YE 2011 through 2012

• Commercial prototype development in 2012

Annual recurring revenue @ one reading/day

Total annual market size for device sales

Annual recurring revenue @ five readings/day

$125 $250

$625

$1,250

5% 10% 25% 50%Market penetration*

5% 10% 25% 50%

Market penetration*

5% 10% 25% 50%Market penetration*

*Does not include any assumption of growth in diabetic market.

8

$456 $913

$2,281

$4,563

$2,281 $4,563

$11,406

$22,813

Glucose-Sensing Microchip (GlucoChip) From our historical base with the original VeriChip – the shift from

identification to diagnostic In vivo glucose-sensing RFID microchip, the GlucoChip™, based on

PositiveID’s Patent No. 7,125,382 for Embedded Bio-Sensor System and Receptors’ patented CARA™ platform Filed additional utility patent covering the interface between an RF powered

resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient

GlucoChip will lie completely under the skin to provide continuous glucose sensing; communicates glucose levels to an external scanner

Phase II development completed – successfully created a stable, reproducible glucose-sensing system and filed related patent

GlucoChip could negate the need for diabetics to prick their fingers multiple times per day: the “Holy Grail” of diabetic treatment

According to the American Diabetes Association, 25.8 million people in the U.S., or 8.3% of the population, have diabetes

Annual cost of treating diabetics in U.S. exceeds $110 billion; expected to triple in 25 years, reaching $336 billion*

* According to University of Chicago research published in Diabetes Care, November 2009

9

GlucoChip Design

BIOCOMPATABLE MEMBRANE

BLOODSTREAM GLUCOSE

SIGNAL TRANSDUCTIONAND RFID ELECTRONICS

GLUCOSE BINDING ENVIRONMENT

COMPETITION/SIGNALING COMPONENT

Integrated sensor device design

Application Specific Integrated Circuit(electrical sensor circuitry)

Antenna coil(RFID enabled communication)

Mass Signal Detection

Reference Environment(No receptors)

Competition /Signaling Component

Biocompatible membrane

Bloodstream Glucose

Glucose Binding Environment(Receptors in crystal)

Glucose Sensor Complete Assembly – Mass Detection Type

SENSING SYSTEM

SENSOR ELECTRONICS

Components of the sensing/communication device

10

GlucoChip Market Opportunity

Assumptions

• Total market size equals 25 million diabetics in the U.S.

• End user sale price of $90 per device• Estimated one-year life of device• No sales of scanners or other revenue

streams assumed

(Device sales in $ millions on annual basis)

Timeline

• Sensing system completed in Q3 2011

• Membrane diffusion and biocompatibility testing Q4 2011-Q1 2012

• Sensor optimization and development of MEMS through mid-2012

• ASIC development and miniaturization mid-2012 - early 2013

• Animal testing and commercial partner Q1 2013

Total market size for device sales

5% 10% 25% 50%

Market penetration*

*Does not include any assumption of growth in diabetic market.

11

$113

$225

$563

$1,125

MicroFluidic Systems

MFS specializes in the development and production of automated systems for a wide range of applications in the detection and processing of biological samples

Founded in 2001, MFS has received over $45 million in government and commercial contracts in the last 10 years

Core technologies include sample prep, nucleic acid (DNA and RNA) and protein detection, automated fluidics and integrated systems

Focused on homeland security and pathogen diagnostic testing (field/clinical/ hospital) opportunities

Strong IP portfolio (29 U.S. Patents and Patents pending) and world-class scientific expertise

Acquired in May 2011; initial consideration of $1.4 million, primarily paid in stock. Additional earn-out of $7.0 million over four years based on revenue and earnings targets

12

M-BAND Overview

M-BAND Integrated Pathogen Detection Systems Bio-aerosol monitors with fully integrated systems with sample collection,

processing and detection modules. Each module is fully functional and adaptable. MFS has implemented its own biological assays.

Key technologies: Multiplexed assays Networked, remotely operating Cell lysis, nucleic acid purification Homogeneous, Taqman PCR Monoclonal antibody-based toxin detection

Product differentiators: Rapid confirmation High sensitivity Fully autonomous operation Complete integration of sample collection through toxin and

pathogen detection

13

MFS Market Opportunity

BioWatch – M-BAND

Total value of BioWatch opportunity is $3.1 billion over approximately five years

Acquisition of biodetectors and replenishment is expected to be 30-40% of total

We are one of only two potentially qualified biodetector systems suppliers

Net margins of 15-20% expected Updated RFP expected by Q1 2012

Other opportunities

MFS has submitted or in-process bids totaling $40 million, some of which are expected to be awarded in early 2012

Opportunities include HHS, DHS, DTRA (Army) and NASA

14

DragonFly Overview

Dragonfly Integrated Diagnostic Systems Microfluidic cartridges for biological sample processing and detection including

differential extraction cartridges, sample processing and amplification for biodefense applications, and clinical sample processing and detection.

Key technologies: Rapid PCR Amplification Fluorescent detection Microfluidic Disposable Cartridges Automated fluidics Rapid cell lysis, nucleic acid purification

Product differentiators: Fast results with high integrity Affordable, disposable, portable Automated and easy to use Small operating footprint

Applications: Environmental bacteria, e.g. E. coli Clinical samples, e.g. HPV Antibiotic-resistant bacteria, e.g. MRSA Biothreat agents Forensic applications

15

Investment Highlights

Unique, patent-pending technologies addressing large markets with significant unmet needs for new products

Strong management team and outstanding scientists with proven track records

FDA clearance for iglucose received in November 2011 – product launch expected by early 2012

Easy Check clinical studies commenced in Q4 2011 Significant BioWatch opportunity and strong pipeline of $40

million in potential new government contract opportunities Initial partnerships in place

16

Balance Sheet

17

(in 000s) 9/ 30/ 2011 12/ 31/ 2010

AssetsCurrent assets:Cash and cash equivalents 472$ 1,764$ Other current assets 186 1,478 Total current assets 658 3,242

Property and equipment, net 54 49 Goodwill 510 --Intangibles 1,487 --Other Assets 258 24 Total assets 2,967$ 3,315$

Liabilities and Stockholders’ Equity (Deficit)Current liabilities:Accounts payable 851$ 490$ Accrued expenses and other current liabilities 1,164 1,219 Total current liabilities 2,015 1,709

Contingent earnout liability 750 --Stock obligation to related party 3,394 --

Total stockholders’ equity (deficit) (3,192) 1,606 Total liabilities and stockholders’ equity (deficit) 2,967$ 3,315$

Cap Structure

18

(Amounts in thousands)

Current Basic Full Dil.

Common Shares

Insider & Affiliate 38,068 47.4% 43.0%

Public Float 42,314 52.6% 47.8%

Total Shares 80,382 100.0% 90.8%

Preferred Shares 3,697 4.2%

Stock Options 4,144 4.7%

Warrants 304 0.3%

Total Diluted Shares 8,145 5.0%

Fully Diluted 88,527 100.0%

Ownership %